PHARMAC considers funding breast cancer drug Kadcyla advocates have been fighting for

Newshub

7 August 2019 - The Government's drug-buying agency PHARMAC is considering funding three new drugs - including one which advocates have been hard fighting for.

PHARMAC is seeking feedback on whether to fund Alecensa, which treats lung cancer, breast cancer drug Kadcyla and Ocrevus for relapsing multiple sclerosis.

The breast cancer drug Kadcyla has been at the centre of protests and petitions to PHARMAC.

Read Newshub article

Michael Wonder

Posted by:

Michael Wonder